Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, speaks on the inflammatory mechanisms of atopic dermatitis and risk of comorbidities in affected patients.
Although understanding on the pathophysiology of atopic dermatitis (AD) remains limited, the inflammatory mechanisms of the condition have been linked directly and indirectly with several comorbidities, said Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital.
Transcript
Can you explain the pathophysiology of AD and its association with other comorbidities?
To the extent that it's possible, there's a lot we do not know about AD and its pathophysiology. But at least in terms of how to link it to the comorbidities, which is the thrust of the recent publication in the Journal of the American Academy of Dermatology, the links can either be direct or indirect.
For example, filaggrin is a protein in the skin, which has been shown to be one of the biggest risk factors for patients with AD. Either a decrease or absence of filaggrin in the skin has been shown to be a susceptibility. Filaggrin is almost like caulk in the skin and so you can therefore reason that diminution of filaggrin in the skin might lead to increased dryness, increased itch from the inflammation that stems from that dryness, increased risk of infections and allergies, all because that skin barrier is not as intact.
There's also a condition called ichthyosis vulgaris, which shares that same mutation and filaggrin as a contributing factor to the cause of the disease and ichthyosis vulgarities is one of the minor diagnostic criteria of AD or eczema. So there's some direct ways to to link and then there's some indirect ways to link.
If you think about the symptoms of AD or eczema like itch. What does that mean? It means potentially sleep loss. What does that mean? It means potentially decreased quality of life, it means possibly inattention at work, could mean potential confusion with things like [attention-deficit/hyperactivity disorder], some of the other comorbidities that have been linked.
Then finally, if you think about inflammation in general, we have learned a lot about psoriasis in the last few years, another chronic inflammatory skin condition. And we have learned that the inflammation in psoriasis—we've known for years there can be inflammation in the joints called psoriatic arthritis—and we've learned about the seeming increased risk of cardiovascular outcomes and morbidity in patients with psoriasis, presumably through that shared common inflammatory pathway.
So, those are some ways that you can link the pathophysiology of AD, to the extent that we know it, and it's comorbidities.
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More